In conjunction with leading the phase l cancer clinical trials program at Austin Hospital, my main areas of responsibility involve management of patients with solid malignancies, with a particular focus on tumours of the brain, head and neck.

My research interests involve phase 1/2 trials evaluating targeted novel biologic agents and small molecule inhibitors, either alone or in conjunction with standard therapies. As well as the development of investigator initiated clinical trials as I have developed or played a substantial role in the development of over 6 trials and the development and characterization of tumour-specific antibodies, particularly those targeting the EGFR and other members of the ErbB family.